| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
22,790,000 |
| Market
Cap: |
24.16(M) |
| Last
Volume: |
563,483 |
Avg
Vol: |
252,607 |
| 52
Week Range: |
$0.502 - $7 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Durect is a biopharmaceutical company developing therapies derived from its Epigenetic Regulator Program. Larsucosterol (also known as DUR-928), a chemical entity in clinical development, is the primary candidate in Co.'s Epigenetic Regulator Program. A bioavailable small molecule, larsucosterol has been shown in both in vitro and in vivo studies to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival. Co. is conducting a double-blind, placebo-controlled Phase 2b clinical trial called AHFIRM, in which Co. is evaluating larsucosterol's life saving potential in patients with severe alcohol-associated hepatitis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
482,093 |
| Total Buy Value |
$0 |
$0 |
$0 |
$288,249 |
| Total People Bought |
0 |
0 |
0 |
4 |
| Total Buy Transactions |
0 |
0 |
0 |
15 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Langecker Peter |
Chief Medical OfficerOfficer |
• – – |
2006-05-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
800 |
|
- |
|
| Hoffmann Dave |
officerTitle |
– • – |
2006-01-09 |
4 |
OE |
$2.40 |
$115,560 |
I/I |
42,000 |
48,000 |
|
- |
|
| Miksztal Andrew |
officerTitle |
• – – |
2006-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,145 |
|
- |
|
| Theeuwes Felix |
officerTitle |
• – – |
2005-11-29 |
4 |
B |
$4.92 |
$99,098 |
I/I |
20,000 |
1,850,001 |
1.99 |
- |
|
| Brown James E |
President & CEO |
• – – |
2005-11-15 |
4 |
S |
$5.00 |
$1,472,350 |
D/D |
(294,470) |
1,841,530 |
|
- |
|
| Chan Tai Wah |
VP Pharma. Research & Develp. |
• – – |
2005-11-07 |
4 |
S |
$5.00 |
$50,000 |
D/D |
(10,000) |
51,371 |
|
- |
|
| Liu Jean I |
Sr. VP & General Counsel |
• – – |
2005-11-07 |
4 |
S |
$5.00 |
$111,280 |
I/I |
(22,256) |
0 |
|
- |
|
| Brown James E |
President & CEO |
• – – |
2005-09-19 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,000 |
2,136,000 |
|
- |
|
| Brown James E |
President & CEO |
• – – |
2005-09-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
12,000 |
2,138,000 |
|
- |
|
| Neukernons Arnand |
Director |
– • – |
2005-05-25 |
4 |
B |
$3.46 |
$47,747 |
I/I |
13,800 |
75,000 |
2.1 |
- |
|
| Neukernons Arnand |
Director |
– • – |
2005-05-24 |
4 |
B |
$3.46 |
$211,899 |
I/I |
61,200 |
61,200 |
2.1 |
- |
|
| Benito Simon X |
Director |
– • – |
2005-05-19 |
4 |
B |
$3.27 |
$16,350 |
D/D |
5,000 |
10,000 |
2.39 |
- |
|
| Benito Simon X |
Director |
– • – |
2005-05-11 |
4 |
B |
$3.05 |
$15,250 |
D/D |
5,000 |
5,000 |
2.39 |
- |
|
| Theeuwes Felix |
Chairman and CSO |
• • – |
2005-05-10 |
4 |
B |
$2.89 |
$118,928 |
I/I |
40,000 |
1,830,001 |
2.66 |
- |
|
| Mendenhall Paula V |
Sr. VP of OperationsOfficer |
• – – |
2005-01-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,500 |
|
- |
|
| Brown James E |
President & CEO |
• • – |
2004-12-27 |
4 |
GD |
$0.00 |
$0 |
D/D |
20,000 |
2,150,000 |
|
- |
|
| Schreck Thomas A |
Chief Financial Officer |
• • – |
2004-07-29 |
4 |
B |
$1.41 |
$2,115 |
D/D |
1,500 |
1,865,000 |
2.73 |
- |
|
| Theeuwes Felix |
Chairman and CSO |
• • – |
2004-07-28 |
4 |
B |
$1.40 |
$99,400 |
I/I |
71,000 |
1,790,001 |
2.66 |
- |
|
| Schreck Thomas A |
Chief Financial Officer |
• • – |
2004-07-28 |
4 |
B |
$1.39 |
$2,086 |
D/D |
1,500 |
1,863,500 |
2.73 |
- |
|
| Hoffmann Dave |
Director |
– • – |
2004-06-14 |
4 |
B |
$3.24 |
$16,192 |
I/I |
5,000 |
6,000 |
2.1 |
- |
|
| Taylor Michael J |
VP, Non Clinical Research |
• – – |
2004-03-25 |
4 |
S |
$3.10 |
$13,640 |
D/D |
(4,400) |
24,988 |
|
- |
|
| Taylor Michael J |
VP, Non Clinical Research |
• – – |
2004-02-13 |
4/A |
D |
$0.00 |
$0 |
D/D |
(0) |
29,388 |
|
- |
|
| Taylor Michael J |
VP, Non Clinical Research |
• – – |
2004-02-13 |
4 |
S |
$3.00 |
$13,200 |
D/D |
(4,400) |
24,988 |
|
- |
|
| Jian Li |
VP Finance and ControllerOffic |
• – – |
2003-12-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,481 |
|
- |
|
| Brown James E |
President & CEO |
• • – |
2003-11-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
20,000 |
2,170,000 |
|
- |
|
152 Records found
|
|
Page 6 of 7 |
|
|
0.07 (6.19%) 
